Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series By admin / 04/03/2025
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis By admin / 10/23/2024
